AstraZeneca Must Explain Spinal Ailment to Resume Vaccine Trial

Source: Bloomberg

A day after pausing its COVID-19 vaccine trials due to a possible serious neurological problem in one patient, AstraZeneca faced numerous questions about what exactly caused the issue and whether it could be related to the vaccine, according to a Bloomberg News report.

On Tuesday, AstraZeneca and its partner, the University of Oxford, confirmed it had stopped giving patients the experimental shot after a person in the U.K. who was participating in one of their studies got sick, triggering a review of safety data. U.S. National Institutes of Health Director Francis Collins told a Senate committee Wednesday the trial had been halted due to a “spinal cord problem.” 

Read the full article.

Related Content